Drug Discovery (Phylogica)
The Drug Discovery Technology Group and Phylogica, commercialisation vehicle.
Addressing emerging needs of the
The Drug Discovery Technology Group is focused on developing new therapies to target disease-causing interactions between proteins; both inside and outside of cells, as well as the development of 'mimetic' vaccines against discontinuous epitopes.
The research of the unit is funded by contracts with several large pharmaceutical companies via a commercial entity named 'Phylogica,' which was the first spin-off company from the Telethon Institute.
Listed on the Australian Stock Exchange, Phylogica (PYC) is a specialist drug discovery company, which identifies new prototype drugs for large drug company customers. It achieves this by drawing from its own source of billions of unique natural peptide compounds - a new drug class known as "Phylomers".
This collection of more than 10 billion compounds is the source
of its potential new drugs and access to this asset is what has driven
deals and strategic alliances with the international
pharmaceutical giants Roche, MedImmune (AstraZeneca), Pfizer and
Janssen Biotech (Johnson &Johnson) within the last two
These unique collections of Phylomer peptides are strongly protected by a portfolio of 16 patent families, including granted patents in the US and Europe.
Dr Douglas Wilson, Executive Chairman
Dr Paul Watt, CEO
Mr Nick Woolf, CFO and VP Corporate Development
Dr Richard Hopkins, COO and VP Research & Development
Dr Shane Stone, Senior Scientist, Structural Biology and Modelling
Dr Paula Cunningham, Senior Scientist, Assay Development and in vivo biology
Hoffmann, Associate Program Manager, Group Leader Protein
engineering, CPP and Vaccine
Dr Nadia Milech, Associate Program Manager, Group Leader Intracellular Targets and Library Development
Dr Tatjana Heinrich, Associate Program Manager, Group Leader Antimicrobial Discovery